Document ID: chunk:federal_register_of_legislation:F2021L01166:reg:7
Version: federal_register_of_legislation:F2021L01166
Segment Type: reg
Provision Reference: reg 7
Character Range: 1677–3231

7               Kind of injury, disease or death to which this Statement of Principles relates
(1)          This Statement of Principles is about primary myelofibrosis and death from primary myelofibrosis.
Meaning of primary myelofibrosis
(2)          For the purposes of this Statement of Principles, primary myelofibrosis:
(a)          means a chronic, Philadelphia-chromosome negative myeloproliferative neoplasm characterised by bone marrow megakaryocytic proliferation, resulting in the replacement of bone marrow with fibrous tissue, extramedullary haematopoiesis, splenomegaly and leukoerythroblastosis in the blood; and
(b)          excludes:
(i)             myelofibrosis secondary to essential thrombocythaemia, polycythaemia vera or another myeloid neoplasm; and
                 (ii)          secondary myelofibrosis resulting from other causes of bone marrow fibrosis including infections, autoimmune disorders or other chronic inflammatory conditions, hairy cell leukaemia or other lymphoid neoplasms, metastatic malignancies and toxic (chronic) myelopathies.
            Note: Typical clinical manifestations of primary myelofibrosis include fatigue, anaemia, bone pain and night sweats. Patients can be asymptomatic.
Death from primary myelofibrosis
(3)          For the purposes of this Statement of Principles, primary myelofibrosis, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's primary myelofibrosis.
Note: terminal event is defined in the Schedule 1 - Dictionary.